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Introduction  
The extended-spectrum b-lactamases 
(ESBLs) enzymes are plasmid-mediated 
enzymes capable of hydrolyzing and 
inactivating a wide variety of oxyimino 
cephalosporins. Their beta-lactamase genes 
are located on bacterial chromosomes or on 
transferable elements such as plasmids, 
transposons or integrons (Machado et al., 
2005) which play an important role in a 
horizontal transmission of resistance genes. 
The resistance to extended spectrum beta            
lactams is increasingly reported worldwide. 
The first -lactamase was identified in E. 
coli prior to the release penicillin for use in 
the medical practice (Bradford et al., 2001). 
The name of CTX-M enzymes refers to their 
ability to hydrolyze cefotaxime and may 
hydrolyze ceftazidime and cefepime 
(Paterson et al., 2005). It was designated as 
FEC-1 when was isolated from cefotaxime 
resistant E. coli isolates in Japan in 1986 as 
a non TEM and non SHV (Bonnet, 2004). 
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CTX-M-15 subtype of extended spectrum beta lactamase (ESBL) has increased in 
recent years around the world. The management of infections is complicated by the 
increasing prevalence and spectrum of antimicrobial resistance especially ESBL 
producing E. coli. This study is done to determine the prevalence of ESBL 
producing E. coli from different extra-intestinal infections. Hundred E. coli isolates 
have collected from Krishna Rajendra hospital, Mysore, India over a period of 10 
months. The production of ESBLs has investigated using antibiotic disks and by 
Polymerase chain reaction (PCR) and sequencing to determine the CTX-M types. 
Out of 100 E. coli isolates; 94, 91,75, 69, 68 samples and 52 were resistant to 
ampicillin, amoxyclav, cefotaxime, ceftazidime, ceftroxime and cefepime 
respectively while 100, 97,91,90 were sensitive to levofloxacin, doxycycline, 
imipenime and amikacine respectively. PCR results have shown that 84 of E. coli 
strains were positive to CTX-M-15 while 16 of strains were non CTX-M. The 
prevalence of ESBL producing E. coli was found to be 75% and the CTX-M-15 
was the predominant type among extra-intestinal pathogenic E. coli. This was 
significantly higher than the other data available in India which refer to the 
increased of control of dissemination of antibiotic resistance.
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However, in 1989 it was designated as CTX-
M-1 when it was isolated from cefotaxime-
resistant clinical E. coli strains that neither 
produced TEM nor SHV (Paterson et al., 
2005). Currently, there are more than 120 
different CTX-M -lactamases that are 
clustered into five groups (CTX-M-1, -2, -8, 
-9, and-25). The CTX-M family shows 
approximately 40% similarities to TEM and 
SHV beta-lactamases at the amino acid level 
(McCracken 2006). CTX-M depending on 
their amino acid sequence similarities is sub 
classified into five groups: (i) CTX-M-1 
group includes six plasmid-mediated 
enzymes (CTX-M-1, CTX-M-3, CTX-M-10, 
CTX M-12, CTX-M-15, CTX-M-22, CTX-M-
23, CTX-M-28 and FEC-1), (ii) CTX-M-2 
group includes eight plasmid-mediated CTX-
M enzymes (CTX-M-2, CTX-M-4, CTX-M-
4L, CTX-M-5, CTX-M-6, CTX-M-7, CTX-M-
20, and Toho-1), (iii) CTX M-8 group 
includes one plasmid-mediated member, (iv) 
CTX-M-9 group includes nine plasmid-
mediated enzymes (CTX-M-9, CTX-M-13, 
CTX-M-14, CTX-M-16, CTX-M-17, CTX-M-
19, CTX-M-21, CTX-M-27, CTX-M-24) and 
(v) CTX-M-25 group includes the CTX-M-25 
and CTX-M-26 enzymes (Bonnet, 2004). 
Extra-intestinal pathogenic E. coli (ExPEC) 
that can cause infection outside the intestinal 
tract are split up as uropathogenic E. coli 
(UPEC), sepsis associated E. coli (SEPEC), 
or neonatal meningitis associated E. coli 
(NEMEC) which reflect their ability to 
cause disease at multiple anatomical sites 
(Russo et al., 2003 and Dobrindt and 
Hacker, 2008). Pathogenic E. coli as 
intestinal pathogens and extra-intestinal E. 
coli infections are recognized as a major 
source of morbidity, mortality, and 
increased health costs (Hamelin et al., 
2006). Enterobacteriaceae with CTX-M 
enzymes have been associated with both 
hospital-acquired and community infections, 
mostly Escherichia coli from the urinary 
tract in the UK (Karisik et al., 2006). In 
India prevalence of extended-spectrum -
lactamase (ESBL) producing bacteria ranges 
from 23-86% in earlier reports and 63.6% of 
E. coli in 2009 (Anandan et al., 2009). 
Prevalence of ESBLs varies greatly around 
the world and is increasing. The difference 
of the prevalence of ESBLs in certain parts 
of the world may relate to differences in 
cephalosporin usage and methods of 
detecting ESBLs as well as lack of a 
sufficient surveillance system. In this study 
we will determine the prevalence of ESBLs 
and investigate the type of CTX-M among 
E. coli isolates that were isolated from 
different Extra-intestinal infections.   
Materials and Methods  
Bacterial isolates   
A total of 100 of E. coli clinical isolates 
were collected from the Department of 
Microbiology, Krishna Rajendra (K. R.) 
Hospital, Mysore, India. All isolates were 
obtained from different extra-intestinal 
specimens including urine, blood, sputum 
and exudates over a Period of 10 months 
(June 2013 to March 2014). All isolates 
were identified as E. coli by inoculated them 
on MacConky Agar (M.A.) and Eosin 
Methylen Blue (E.M.B.) Agar and by using 
biochemical identification kit (HiE. coli 
Identification Kit, HiMedia Laboratories 
Pvt. Ltd, Mumbai, India).  
Antibiotic sensitivity test  
Antibiotic Sensitivity was determined by 
Kirby-Bauer disk diffusion method as per 
CLSI recommendations (2012). 
Antimicrobial disks used were Ampicillin 
(10 µg), Cefotaxime (30 µg), Cefoxitin (30 
µg), Ceftazidime (30 µg), Gentamicin (10 
µg), Amikacin (30 µg), Cefepime (30 µg), 
Cefuroxim (30 µg), Norfloxacin (10 µg), 
Chloramphenicol (30 µg), Levofloxacin (5 
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µg), Trimethoprim-sulfamethoxazole (25 
µg), Amoxyclav (30µg), Doxycycline 
Hydrochloride (30 µg), Cefpodoxime (10 
µg) and Imipenem (10 µg) (HiMedia, India).   
Screening test for ESBL production   
According to the CLSI guidelines, isolates 
showing inhibition zone size of 22 mm 
with Ceftazidime (30 µg), and  27 mm with 
Cefotaxime (30 µg) were identified as 
potential ESBL producers and shortlisted for 
confirmation of ESBL production.  
Confirmatory test for ESBLs  
Phenotypic confirmatory test of ESBL 
production was performed by a double disc 
synergy test using Hexa disc rings 
(HiMedia, India) that contain three 
antibiotics and three antibiotics with 
clavulanic acid that include cefotaxime (30 
µg), cefotaxime-clavulanic acid (30/10 µg), 
ceftazidime (30 µg), ceftazidime-clavulanic 
acid (30/10 µg) and Cefpodoxim (10µg) and 
Cefpodoxim-clavulanic acid (10/5 µg). Each 
ring was placed on a lawn culture of the test 
isolate on Muller Hinton Agar (MHA) plate 
and incubated overnight at 37 C.  
Interpretation: when there is an increase of 
5 mm in inhibition zone diameter around 
combination disk of Cefotaxime+Clavulanic 
acid versus the inhibition zone diameter 
around Cefotaxime disk alone, it confirms 
ESBL production.   
Determination of CTX-M types By 
Polymerase Chain Reaction (PCR)  
Template DNA was prepared by boiling 
method as described by Ruppe et al., 
2009.The presence of blaCTX-M -
lactamase genes will be screened as 
described previously (Paterson et al., 2003) 
by using primers blaCTX-Mf 5'-
CGCTTTGCGATGTGCAG-3' and 
blaCTX-Mr 5'-ACCGCGATATCGTTGGT-
3' with using the following reaction 
parameters: 35 cycles of ampli cation at a 
denaturation temperature of 94°C for 30 s, 
an annealing temperature of 60°C for 1 min 
and an extension temperature of 72°C for 1 
min. This step was followed by a nal 
extension at 72°C for 10 min. PCR products 
were resolved on 1% agarose gels, stained 
with ethidium bromide, and photographed 
with UV illumination. All positive PCR 
products will send for sequencing to 
investigate the specific types of CTX-M by 
blasting on BLAST website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
Statistical analysis  
Chi square was used to see the significance 
of difference between the production of 
CTX-M in ESBL and non ESBL producer 
strains.   
Result and Discussion  
Hundred E. coli isolates were collected from 
different samples, urine (55%), exudates 
(30%), sputum (8%) and blood (7%).  
Antibiotic sensitivity test  
Out of 100 E. coli isolates; 94, 91,75, 69, 68 
samples and 52 are resistant to ampicillin, 
amoxyclav, cefotaxime, ceftazidime, 
ceftroxime and cefepime respectively which 
are considered as multidrug resistant E. coli 
strains. While 100, 97, 91 and 90 still 
sensitive to levofloxacin, doxycycline, 
imipenime and amikacine respectively as 
shown below in table 1.   
The isolates that showed resistance to 
cefotaxime, ceftazidime, cefepime and 
ceftroxime are considered as ESBL 
producers and it confirmed by double disk 
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synergy test using combined antibiotics 
(cefotaxime, ceftazidime and cefpodoxim) 
with clavulanic acid (Fig. 1). The antibiotic 
sensitivity results are explored in the graph 
(Fig. 2).   
Determination of CTX-M types  
Out of 100 E. coli strains 84 are positive for 
CTX-M gene subtype CTX-M15 while 16 of 
strains are non CTX-M producers as figure 
3.  
Compression of the strains related to its 
resistance to cefotaxime and production of 
CTX-M enzyme we found that 81 of E. coli 
strains are resistant and intermediate to 
cefotaxime and producing to CTX-M while 
6 strains are resistant to cefotaxime but not 
producing CTX-M. However, 9 strains of E. 
coli are sensitive to cefotaxime are CTX-M 
producers. The difference between the 
production of CTX-M of ESBLs and non 
ESBLs producing E. coli was significant 
(P=0.00 0.05).   
Out of 100 E. coli isolates, 94, 91, 75, 69, 68 
samples and 52 are resistant to ampecillin, 
amoxyclav, cefotaxime, ceftazidime, 
ceftroxime and cefepime, respectively. 
While 100, 97, 91 and 90 still sensitive to 
levofloxacin, doxycycline, imipenime and 
amikacine respectively. This result is agree 
with Datta et al. (2004) and Anandan et al. 
(2009) with the exception for amikacine and 
gentamicine which last report showed the 
isolates were resistant for it. 35 % of isolates 
are resistant to gentamicine while another 
study (Umadevi et al., 2011) showed 100% 
of E. coli were sensitive to gentamicine. 
Recently, prevalence of ESBL producing E. 
coli has been increasing over the past years, 
resulting in limitation options. In current 
study 75% of E. coli strains are ESBL 
producers related to their resistance to 
cefotaxime and the increase of zone 
inhibition of cefotaxime with clavulanic 
acid. It is a high percentage of ESBLs 
regarding to another study which reported 
that the prevalence of ESBL-E. coli was 
18.5%, 22%, 38.4% and 60% among UTI 
infections (Agrawal et al., 2008; Rajan and 
Prabavathy, 2012) and (Narayanaswamy and 
Mallika, 2010) respectively, but it 
compatible with another study (Freeman et 
al., 2008) which reported that 90% of 
patients who travelled from New Zealand to 
India are infecting by ESBLs E. coli. The 
differences in the prevalence of ESBLs 
producing E. coli between the regions may 
refer either to the randomly consuming of 
antibiotics or to the different endemic 
strains. Genotypic analysis of CTX-M 
enzyme showed all CTX-M producing E. 
coli are carrying CTX-M-15. It is a high 
percent in comparison with previous study 
which found CTX-M-15 in different 
countries in different percent 45% and 
96.77% (Kingsley et. al., 2008 and Al-
Agamy et al., 2014). The travelling between 
different countries may play an important 
role in dissemination of ESBLs among 
different pathogens as what was reported by 
Yaita (2014) who reported that the travel to 
India was a risk factor (Odds Ratio 13.6, 
95% Confidence Interval 3.0 75.0, 
p,0.0001) and the dissemination of CTX-M-
15 was 77%. Another study (Freeman et al., 
2008) reported that 90% of patient who 
travelled to India was infected by ESBL-E. 
coli and 88.88% of them were carrying 
CTX-M-15. In comparison the E. coli 
isolates related to their resistance to 
cefotaxime and production of CTX-M 
enzyme, we found that not all cefotaxime-
resistant isolates producing of CTX-M, 
which 6 isolates were not producing of 
CTX-M. These isolates may carry another 
beta-lactamase gene which are not including 
in this study. On contrary 6 isolates that 
were sensitive to cefotaxime showed 
positive to CTX-M gene which can be 
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interpreted by these isolates contain CTX-M 
gene but still not express it or may exposed 
to external effects that disrupted the gene. 
Related to the previous and recent studies, 
the prevalence of CTX-M-15 has increased 
so fast around the world. This finding may 
refers to the randomly using of antibiotics or 
the combination of antibiotic resistance with 
specific epidemiological strains which make 
the control of dissemination of antibiotics 
resistance is difficult and the infections 
cannot be treatment.  
Prevalence of CTX-M-15 has increased 
among E. coli infections in compression to 
previous studies which may refer to some 
epidemiological strains may disseminate that 
was harboring CTX-M-15. Many studies 
should be done to investigate the 
epidemiological E. coli strains with their 
phylogenetic groups which may refer to the 
source of infection to control the 
dissemination of ESBLs.    
Table.1 Antibiotics sensitivity test  
Antibiotics R I S 
CTX 75 6 19 
AMP 94 0 6 
CAZ 69 7 24 
GEN 35 8 57 
AK 10 0 90 
CPM 52 12 36 
IPM 8 1 91 
AMC 91 6 3 
CX 29 8 63 
C 12 14 74 
COT 46 17 37 
LE 0 0 100 
CXM 68 6 26 
NX 43 14 43 
DO 0 3 97 
AMP; Ampicillin, CTX; Cefotaxime, CX; Cefoxitin, CAZ; Ceftazidime, GEN; Gentamicin, AK; Amikacin, CPM; 
Cefepime, CXM; Cefuroxim, NX; Norfloxacin, C; Chloramphenicol, LE; Levofloxacin, COT; Trimethoprim-
sulfamethoxazole, AMC; Amoxyclav, DO; Doxycycline Hydrochloride and IPM; Imipenem   
Figure.1 A, B; Antibiotic sensitivity test using Antibiotic discs, C; ESBL  
confirmation test using Hexa disc rings  
 
Int.J.Curr.Microbiol.App.Sci (2015) 4(5): 243-250   
248
 
Figure.2 Antibiotic sensitivity test  
 
Figure.3 PCR Result of CTX-M: Lane M; DNA Marker, Lanes 1-11 refer to sample No.; D59, 
U12, S3, E24, U-5, U-55, U-43, S-10, E56, E-8, and E-62 are positive to CTX-M  
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